CYP2C19基因多态性与氯吡格雷的应用及替代治疗的研究进展  

Research progress on CYP2C19 genetic polymorphism and the application and replacement therapy of clopidogrel

作　　者：吴浪[1,2] 杨胜利[1,2] 

机构地区：[1]安徽医科大学武警总医院临床学院,北京100039 [2]武警总医院心内科,北京100039

出　　处：《中华灾害救援医学》2016年第6期336-340,共5页Chinese Journal of Disaster Medicine

摘　　要：在急性冠状动脉综合征(acute coronary syndrome,ACS)和经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后的患者中,阿司匹林联合氯吡格雷双联抗血小板治疗是降低血栓形成及缺血性事件发生的风险的常规治疗。细胞色素P450 2C19(cytochrome P450 2C19,CYP2C19)基因多态性影响氯吡格雷的药效学和药动学,增加PCI术后患者缺血性事件发生的风险。根据CYP2C19基因多态性调整PCI术后氯吡格雷的应用具有一定的指导价值。笔者将对CYP2C19基因多态性与氯吡格雷的应用及替代治疗的研究进展进行综述。Dual antiplatelet therapy of aspirin and clopidogrel is conventional to patients with acute coronary syndrome（ACS） and undergoing percutaneous coronary intervention（PCI） to reduce the risk of thrombosis and ischemic events. Genetic polymorphisms of cytochrome P450 2C19（CYP2C19） affects the pharmacokinetics and pharmacodynamics of clopidogrel, which could improve the risk of ischemic events for patients after PCI. Therefore, it is of great value to guide the application of clopidogrel according to the genetic polymorphisms of CYP2C19. In this paper, the research progress of CYP2C19 geneticpolymorphism and the application and replacement therapyof clopidogrel is reviewed.

关 键 词：CYP2C19基因多态性 氯吡格雷 经皮冠状动脉介入治疗 

分 类 号：R541.4[医药卫生—心血管疾病]